GlassScriptPhysician profile
Joseph P Bast
NPI 1124287131
$4,849.58
in general payments reported to CMS, 2019-2025
30 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $108 · 2021: $199 · 2022: $591 · 2023: $642 · 2024: $1,106 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,764 · Education: $67.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,763.84 |
| Education | $67.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $513.05 | 2019-2024 | Lokelma, Farxiga |
| Vantive US Healthcare LLC | $443.89 | 2025 | Renal - Pd, Renal - Chronic |
| Nxstage Medical, INC. | $408.55 | 2020-2025 | Nxstage System One, Liberty Select Cycler, Nxstage Cartridge Express |
| Bard Peripheral Vascular, INC. | $383.48 | 2023-2024 | Pristine |
| Medtronic, INC. | $338.39 | 2024-2025 | Symplicity G3 |
| Ani Pharmaceuticals, INC. | $320.47 | 2023-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $260.75 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $240.51 | 2021-2025 | Acthar |
| Baxter Healthcare | $195.78 | 2020-2022 | |
| Vifor Pharma, INC. | $177.04 | 2022-2025 | Veltassa |
| Abbott Laboratories | $169.17 | 2025 | Cardiomems |
| Scpharmaceuticals INC. | $153.69 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $149.91 | 2024-2025 | |
| Amgen INC. | $140.82 | 2024-2025 | Tavneos, Aranesp, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.17 | 2024-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $132.20 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $101.90 | 2024-2025 | Jynarque, Voyxact |
| Ardelyx, INC. | $87.75 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $70.38 | 2023-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $68.19 | 2023-2025 | Benlysta, Jesduvroq, Arexvy |
| Lilly USA, LLC | $64.07 | 2024-2025 | Jardiance |
| Edwards Lifesciences Corporation | $63.54 | 2024 | Hemosphere |
| Fresenius USA Marketing, INC. | $62.55 | 2024-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $42.18 | 2025 | Wegovy |
| Mozarc Medical US LLC | $40.41 | 2024 | Palindrome |
| Genzyme Corporation | $25.28 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.04 | 2025 | Ultomiris |
| Lexicon Pharmaceuticals, INC. | $15.50 | 2024 | |
| Ascendis Pharma Endocrinology INC | $13.48 | 2025 | Yorvipath |
| Boston Scientific Corporation | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.